Showing results (31-40 of 98) with videos related to

Sort By:
Pageof 10
Journal of Hematology & Oncology|May 8, 2012
Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndromeNaomi Galili, Pablo Tamayo, Olga B Botvinnik, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 8, 2008
Erythroid-predominant myelodysplastic syndromes: enumeration of blasts from nonerythroid rather than total marrow cells provides superior risk stratificationSa A Wang, Guilin Tang, Oluwole Fadare, et al.
Leukemia Research|October 27, 2006
Clinical response of myelodysplastic syndromes patients to treatment with coenzyme Q10Naomi Galili, Eric V Sechman, Jan Cerny, et al.
Leukemia Research|January 24, 2007
Bone biopsy derived marrow stromal elements rescue chronic lymphocytic leukemia B-cells from spontaneous and drug induced cell death and facilitates an "angiogenic switch"Neil E Kay, Tait D Shanafelt, Ann K Strege, et al.
Future Oncology (London, England)|June 22, 2006
Can molecular profiling of cytogenetic subgroups draw a roadmap for individualizing therapy in myelodysplastic syndromes?Naomi Bruce Galili, Murtaza Mehdi, Muhammad Mumtaz, et al.
International Journal of Hematology|October 16, 2004
Increased levels and activity of E2F1 transcription factor in myelodysplastic bone marrowGurveen Saberwal, Steven Lucas, Imke Janssen, et al.
Scientific Reports|April 28, 2018
Survey and evaluation of mutations in the human KLF1 transcription unitMerlin Nithya Gnanapragasam, John D Crispino, Abdullah M Ali, et al.
Hematological Oncology|April 30, 2014
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapyLewis R Silverman, Peter Greenberg, Azra Raza, et al.
British Journal of Haematology|June 25, 2013
Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromesRami S Komrokji, Azra Raza, Jeffrey E Lancet, et al.
Leukemia Research|August 7, 2007
Flow cytometric analysis of myelomonocytic cells by a pattern recognition approach is sensitive and specific in diagnosing myelodysplastic syndrome and related marrow diseases: emphasis on a global evaluation and recognition of diagnostic pitfallsDariusz Stachurski, Brian R Smith, Olga Pozdnyakova, et al.
Pageof 10